Danaher (NYSE:DHR) Reaches New 52-Week High at $147.76

Share on StockTwits

Danaher Co. (NYSE:DHR)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $147.76 and last traded at $146.90, with a volume of 83317 shares traded. The stock had previously closed at $146.69.

A number of research analysts have recently commented on DHR shares. UBS Group raised their price target on Danaher from $158.00 to $165.00 and gave the company a “buy” rating in a report on Monday. Wolfe Research set a $154.00 price objective on shares of Danaher and gave the stock a “buy” rating in a report on Friday, October 25th. ValuEngine lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Needham & Company LLC lowered their target price on shares of Danaher from $155.00 to $152.00 and set a “buy” rating on the stock in a research note on Monday, October 28th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $150.00 target price on shares of Danaher in a research note on Thursday, November 14th. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $147.53.

The company has a debt-to-equity ratio of 0.52, a current ratio of 3.43 and a quick ratio of 3.09. The business has a fifty day moving average of $139.57 and a 200-day moving average of $139.66. The stock has a market capitalization of $104.85 billion, a price-to-earnings ratio of 32.41, a price-to-earnings-growth ratio of 2.45 and a beta of 0.92.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Thursday, October 24th. The conglomerate reported $1.16 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.15 by $0.01. The company had revenue of $5.04 billion during the quarter, compared to the consensus estimate of $5.02 billion. Danaher had a net margin of 12.13% and a return on equity of 11.42%. Danaher’s revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the company earned $1.10 EPS. As a group, research analysts anticipate that Danaher Co. will post 4.76 EPS for the current year.

Large investors have recently modified their holdings of the stock. Howe & Rusling Inc. lifted its holdings in shares of Danaher by 116.3% during the third quarter. Howe & Rusling Inc. now owns 186 shares of the conglomerate’s stock valued at $27,000 after purchasing an additional 100 shares during the last quarter. Next Capital Management LLC purchased a new position in shares of Danaher in the second quarter worth approximately $31,000. Litman Gregory Asset Management LLC purchased a new position in shares of Danaher in the second quarter worth approximately $33,000. Altshuler Shaham Ltd increased its position in shares of Danaher by 59.3% in the second quarter. Altshuler Shaham Ltd now owns 239 shares of the conglomerate’s stock worth $34,000 after acquiring an additional 89 shares in the last quarter. Finally, Pinnacle Bank raised its holdings in shares of Danaher by 52.3% during the third quarter. Pinnacle Bank now owns 262 shares of the conglomerate’s stock valued at $38,000 after acquiring an additional 90 shares during the period. Hedge funds and other institutional investors own 78.10% of the company’s stock.

About Danaher (NYSE:DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Featured Article: Understanding Relative Strength Index

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.